Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2851)	5/19/2010 2:12:00 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

BIOD is trading near its intraday H and is up 4.17% on volume >281Ks already above its ADV bigcharts.marketwatch.com The stock found recent support at the $5 level and was able to make a 52wks H on May 10 at $6.25 The question is now how much it will be able to close of its DG of Sep5-12 in 2008 <g> bigcharts.marketwatch.com BIOD has no significant LTD But has been burning its cash at a fast clip. It has a pretty large negative CF It was able to trim some its loss on the 2ndQ, the results of which it reported earlier this month. It cut its RAD expenses by $1.4M, as patients completed the PIII extension trials for VIAject in February. It also reduced manufacturing expenses due to purchasing of a reduced amount of recombinant human insulin. BIOD did not recognize any revenue during the Q.<g> At the end of the Q it had cash of $32.7M and 23.9M shrs out. In Feb it said that the FDA has accepted for review its NDA to market VIAject as a treatment for diabetes. BIOD has responded to the FDA’s 74-day letter regarding the NDA and recently submitted a 120-day safety update on patient experience with the drug, including data from the recently completed VIAject PIII extension trials. BIOD presented results from the VIAject program at the Deutsche Diabetes Gesellschaft meeting in Germany last week. It will be presenting a number of abstracts on several of its product candidates at the ADA’s annual meeting next month. The ACTAY is $14.75 As mentioned,the stock has resistance at $6 and then at the May10 H, before trying to find out how much of its Sep2008 DG it will be able to close.<g> bigcharts.marketwatch.com Bernard